Donald Gravenor

523: CIRCULATING TUMOR DNA FOR DETECTION OF MOLECULAR RESIDUAL DISEASE (MRD) IN PATIENTS (PTS) WITH STAGE II/III COLORECTAL CANCER (CRC): FINAL ANALYSIS OF THE BESPOKE CRC SUB COHORT

Kim Magee, Purvi K. Shah, Vasily N. Aushev, Joe Ensor et autres

Circulating tumor DNA for detection of molecular residual disease (MRD) in patients (pts) with stage II/III colorectal cancer (CRC): Final analysis of the BESPOKE CRC sub-cohort.

Purvi K. Shah, Vasily N. Aushev, Joe Ensor, Stephanie Sanchez et autres

us (code pays fourni par la source)

Patient-reported outcomes from the BESPOKE CRC study.

Pashtoon Murtaza Kasi, Samuel Rivero-Hinojosa, Vasily N. Aushev, Nathan Langer et autres

us (code pays fourni par la source)

Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

Pashtoon Murtaza Kasi, Vasily N. Aushev, Joe Ensor, Nathan Langer et autres

us (code pays fourni par la source)

Clinical, operative, and pathologic outcomes following neoadjuvant therapy versus upfront surgery for ampullary, duodenal and distal bile duct adenocarcinoma

D. Patel, Aleksander Jankov, Donald Gravenor, R. Sroufe et autres

Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial

Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois et autres

us, de, fr, pl, kr, Éthiopie, it (code pays fourni par la source)

Phase 1b results of avelumab in patients (pts) with previously treated metastatic melanoma enrolled in the JAVELIN Solid Tumor trial, including updated subgroup analyses.

Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois et autres

de, us, fr, pl, kr (code pays fourni par la source)

Avelumab in patients with previously treated metastatic melanoma: Phase 1b results from the JAVELIN Solid Tumor trial.

Ulrich Keilholz, Janice M. Mehnert, Sebastian Bauer, Hugues Bourgeois et autres

de, us, fr, pl, kr (code pays fourni par la source)

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Denise A. Yardley, Edward Arrowsmith, Brooke Daniel, Janice F. Eakle et autres

us (code pays fourni par la source)

Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy

James R. Berenson, James Hilger, Ori Yellin, Robert Dichmann et autres

us, cn (code pays fourni par la source)

Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).

James R. Berenson, James Hilger, Robert Dichmann, Dipti Patel‐Donnelly et autres

us (code pays fourni par la source)

Abstract P1-14-14: Neoadjuvant Sunitinib (S) Administered with Weekly Paclitaxel (P)/Carboplatin(C) in Patients (Pts) with Locally Advanced Triple-Negative Breast Cancer (TNBC): Preliminary Results from a Phase I/II Trial of the Sarah Cannon Research Institute.

DA Yardley, J. Barton, Carolyn B. Hendricks, Charles Webb et autres

us (code pays fourni par la source)